A joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services, Blue Knight is dedicated to activating the global innovation community, accelerating and amplifying scientific and technological advancements with the aim to anticipate potential health security threats, prepare for and respond to our rapidly evolving global health environment.
Since the initiative’s official launch in August 2020, 16 companies in North America have been accepted into the initiative and are receiving the benefit of access to resources and support from both BARDA and Johnson & Johnson Innovation – JLABS (‘JLABS’). We are continuing to accept applications on a rolling basis for residency at select JLABS locations, or through a virtual engagement option.
One Blue Knight company example is our collaboration between Janssen Oncology and Persephone Biosciences, an early-stage innovation JLABS @ San Diego resident and Blue Knight company, whose aim is to advance the science of the gut microbiome to develop precision treatments and diagnostics with a focus towards disease prevention.
Our partnership with Johnson & Johnson Innovation – JLABS is bringing forward early innovative ideas, entrepreneurs and startup companies that help protect against possible health impacts of the many evolving threats to our nation’s security and, potentially save lives. We’re excited to be bringing subject matter expertise to the table to help.
Gary L. Disbrow, Ph.D.
Director, Biomedical Advanced Research and Development Authority,
Deputy Assistant Secretary for Preparedness and Response U.S.
Department of Health and Human Services